Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 in Relapsed or Refractory DLBCL
NCT02361346Phase 2Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Feb 2015
- Primary completion
- Mar 2021
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 2 trial of MT-3724 in diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by Molecular Templates, Inc.. Started Feb 2015; status: terminated.
02
Drugs
MT-3724
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02361346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361346.